Cancer anti-sickness drug offers hope for hallucinations in Parkinson’s – Parkinson’s UK

Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, is partnering with UCL, and investing £1 million in a pioneering phase 2 clinical trial to explore if the drug ondansetron is safe and effective against hallucinations.

There are currently 145,000 people living with Parkinson’s in the UK and 75% of them will experience visual hallucinations at some point.

Click here to read full article

Leave a Reply

Your email address will not be published. Required fields are marked *

Font Resize